CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Bullish +65

From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here - 24/7 Wall St.

📈 Piper Sandler raises CRISPR Therapeutics price target to $110 from current levels of ~$49.37, implying over 120% upside.

💰 Company issued a $600M convertible note due March 2031, resulting in $2.56B pro forma cash and extended runway.

📊 Approved gene therapy CASGEVY generated $116M revenue in 2025 with patient initiations nearly tripling year-over-year.

👶 Pediatric label expansion for CASGEVY (ages 5-11) is under submission with FDA approval expected in H1 2026.

❤️ Cardiovascular program CTX310 advanced to Phase 1b following strong early data published in the New England Journal of Medicine.

🧬 Pipeline includes CTX340 for refractory hypertension, zugo-cel for autoimmune diseases, and CTX611 advancing simultaneously.

📉 Stock is down 8% year-to-date but maintains 79% institutional ownership with an Overweight rating from Piper Sandler.

⚠️ Primary risk remains significant operating losses with no near-term path to profitability requiring flawless execution.

Bullish Signals
  • Piper Sandler raised the price target to $110, signaling strong institutional confidence in the company's long-term value proposition despite recent share price declines.
  • The issuance of a $600 million convertible note has secured $2.56 billion in pro forma cash, eliminating the immediate need for dilutive equity raises and allowing focus on clinical development.
  • CASGEVY demonstrated robust commercial momentum with $116 million in 2025 revenue and patient initiations nearly tripling year-over-year to 30 infusions in Q4 alone.
  • The upcoming pediatric label expansion for CASGEVY covering ages 5-11 is expected in H1 2026, which could meaningfully expand the addressable market for the approved therapy.
  • CTX310 has demonstrated strong early results in cardiovascular disease published in the New England Journal of Medicine, advancing to Phase 1b and potentially reframing the company's long-term revenue profile.
  • Deep cash reserves enable CRISPR to advance multiple high-value programs like CTX340, zugo-cel, and CTX611 simultaneously without financial constraints or dilution.
Risk Factors
  • CRISPR Therapeutics continues to generate significant operating losses with no near-term path to profitability, making execution on every pipeline milestone non-negotiable.
  • Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes and successful FDA approval of the pediatric label expansion.
  • The stock has recently dropped 5% over the past week and is down 8% year-to-date, reflecting ongoing market volatility typical for pre-profitability biotech companies.
Full Analysis
CRISPR Therapeutics (NASDAQ: CRSP) shares have recently declined, trading around $49.37 after dropping 5% in the past week and 8% year-to-date. Despite this short-term weakness, investment firm Piper Sandler has raised its price target to $110, implying over 120% upside potential from current levels. The analyst maintains an Overweight rating on the stock, citing a strengthened balance sheet and significant commercial momentum as key drivers for future growth. The primary catalyst for the bullish outlook is a freshly issued $600 million convertible note due in March 2031, which provides the company with pro forma cash of $2.56 billion. This substantial liquidity extends CRISPR's runway to advance multiple pipeline programs through clinical development without the need for near-term capital raises, effectively de-risking the pre-profitability biotech. Additionally, its approved gene therapy, CASGEVY, generated $116 million in full-year 2025 revenue with patient initiations nearly tripling year-over-year. Beyond commercial success, CRISPR is advancing a robust cardiovascular pipeline, specifically CTX310, which has shown strong early results published in the New England Journal of Medicine and is moving toward Phase 1b. The company also plans to expand CASGEVY's pediatric label for ages 5-11 with regulatory submissions expected in the first half of 2026. With deep cash reserves, CRISPR can simultaneously advance programs like CTX340 for hypertension and zugo-cel for autoimmune diseases without dilutive equity raises. Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes, FDA approval of the pediatric label expansion, and successful readouts from cardiovascular or autoimmune pipeline candidates. While CRISPR continues to generate significant operating losses with no near-term path to profitability, making execution on every milestone non-negotiable, Piper Sandler views the $110 target as a credible long-term value case for investors willing to accept biotech-level volatility.